Nurix Therapeutics has been granted a patent for compounds that degrade BTK through a ubiquitin proteolytic pathway. The invention includes pharmaceutical compositions and treatment methods for various diseases. GlobalData’s report on Nurix Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Nurix Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Nurix Therapeutics's grant share as of February 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11866442B2) discloses a compound of Formula (A) and its pharmaceutically acceptable salts, with various specific configurations outlined in the claims. The compound is designed to target and degrade Bruton's tyrosine kinase, offering potential therapeutic applications in treating diseases or disorders mediated by this enzyme. The patent covers a range of structural variations and compositions, including pharmaceutical compositions comprising the compound and suitable carriers. Additionally, the patent details a method for treating diseases such as cancer or autoimmune conditions by administering the disclosed compound or its salts, showcasing a broad spectrum of potential therapeutic uses.
The patent's claims also extend to specific applications in treating hematological cancers like leukemia, lymphomas, and myeloma, as well as autoimmune diseases ranging from lupus and rheumatoid arthritis to rare conditions like paraneoplastic cerebellar degeneration and POEMS syndrome. The compound's versatility in targeting Bruton's tyrosine kinase opens up possibilities for novel treatment approaches in a wide array of diseases, emphasizing the potential impact of this innovation in the field of pharmaceuticals. With detailed descriptions of structural elements and their variations, the patent provides a comprehensive framework for developing targeted therapies that could address unmet medical needs across various disease categories, marking a significant advancement in the quest for effective treatments in oncology and autoimmune disorders.
To know more about GlobalData’s detailed insights on Nurix Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
